RxDoctor Payments Data

Kristin Scott-Tillery, MD

Advanced Heart Failure and Transplant Cardiology · Billings, MTNPI 1730305095

Payments from drug & device makers

$206,938in general payments, 2019–2025

Across 145 payments — averaging $1427.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$204K
  • Amgen$1K
  • Impulse Dynamics (USA) Inc.$402
  • Actelion Pharmaceuticals US, Inc.$379
  • Boston Scientific$266
  • Abbott$204
  • plus $380 from 5 others

What the payments were for

  • Consulting fees$3,0001%
  • Speaking & faculty fees$163,76280%
  • Travel & lodging$35,31817%
  • Food & beverage$3,4932%
  • Education$1650%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Montanato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$50,679
Medicare patients
318
Services billed
544

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat12$169,323
EliquisApixaban109$121,028
EntrestoSacubitril/Valsartan82$86,525
JardianceEmpagliflozin96$84,661
FarxigaDapagliflozin Propanediol47$50,716
XareltoRivaroxaban11$15,149
Potassium Chloride90$3,050
Metoprolol Succinate159$2,211
Spironolactone201$1,351
Furosemide153$972
Carvedilol98$925
Eplerenone16$731
Atorvastatin Calcium94$726
Torsemide41$689
Bumetanide12$548

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$133$50,71647 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Montanaon file to place this against a meaningful peer group, so we don't.

Where these figures come from

Is this you, or does something look wrong? →